Translation for cancer therapeutics is taking too long and costing too much, according to Dr. Philip Schein, visiting professor in cancer pharmacology at the University of Oxford in England and leading international authority in the treatment of cancer. How can we improve in the future? Join host Dr. Bruce Bloom's conversation with Dr. Schein and Scott Riccio, founder and director for Accelerate Progress, a not-for-profit "action-tank" focused on bringing new promising and potentially lifesaving therapies to cancer patients, about why and how we should truncate the lengthy approval process and decrease the costs of bringing new therapeutics to market.
advertisement
Speeding Up Translation of New Cancer Therapeutics
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
Translation for cancer therapeutics is taking too long and costing too much, according to Dr. Philip Schein, visiting professor in cancer pharmacology at the University of Oxford in England and leading international authority in the treatment of cancer. How can we improve in the future? Join host Dr. Bruce Bloom's conversation with Dr. Schein and Scott Riccio, founder and director for Accelerate Progress, a not-for-profit "action-tank" focused on bringing new promising and potentially lifesaving therapies to cancer patients, about why and how we should truncate the lengthy approval process and decrease the costs of bringing new therapeutics to market.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
advertisement
Recommended
CME/CE
IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy
0.25 credits
<p>IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy</p>
CME/CE
IgG4-RD Case Conversations: IgG4-related Autoimmune Pancreatitis and Cholangitis
0.25 credits
<p>IgG4-RD Case Conversations: IgG4-related Autoimmune Pancreatitis and Cholangitis</p>
MinuteCE®
Clinical Practice Guidelines for Hyperlipidemia: What Are the Recommendations?
0.75 credits
<p>Clinical Practice Guidelines for Hyperlipidemia: What Are the Recommendations?</p>
MinuteCE®
Combination Therapies: Approaches for Getting to Goal Quickly vs Titration Over Time
0.75 credits
<p>Combination Therapies: Approaches for Getting to Goal Quickly vs Titration Over Time</p>
CME/CE
TIME OUT: A Case-Based Deep Dive into the Challenges of ARIA Management
0.50 credits
<p>TIME OUT: A Case-Based Deep Dive into the Challenges of ARIA Management</p>
CME/CE
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
0.50 credits
<p>New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure</p>
MinuteCE®
Clinical Conundrums in ARIA: Nuances of Microhemorrhages when Evaluating an MRI for ARIA
1.25 credits
<p>Clinical Conundrums in ARIA: Nuances of Microhemorrhages when Evaluating an MRI for ARIA</p>
MinuteCE®
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
0.75 credits
<p><span data-contrast="none" style="list-style-type: disc;" xml:lang="EN-US">The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC</span></p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?